Premium
bel‐2 protein in breast cancer cells obtained by fine needle aspiration (FNA): a preliminary report
Author(s) -
TRONCONE G.,
ZEPPA P.,
VETRANI A.,
D'ARCANGELO A.,
FULCINITI F.,
DIVITIIS B.,
PALOMBINI L.
Publication year - 1995
Publication title -
cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.512
H-Index - 48
eISSN - 1365-2303
pISSN - 0956-5507
DOI - 10.1111/j.1365-2303.1995.tb00473.x
Subject(s) - concordance , medicine , breast cancer , fine needle aspiration , apoptosis , pathology , involution (esoterism) , cancer , cancer research , biopsy , biology , consciousness , biochemistry , neuroscience
The bcl‐2 protein plays a role in the regulation of programmed cell death (PCD), overriding apoptosis. Its expression has been reported in breast ductal cells, where it is believed to be involved in the hormonal regulation of hyperplasia and involution. to date, bcl‐2 gene product has not been investigated on breast cancer FNA. the expression of bcl‐2 protein was evaluated using an immunoalkaline phosphatase technique in 54 pre‐operative breast cancer aspirates and in paraffin‐embedded sections from 20 matched surgical specimens. A high rate of bcl‐2 protein expression was found on FNA samples (65%) and on the corresponding tissue sections (60%); there was a nearly absolute concordance in the two specimens, with 19/20 (95%) cases showing a concordant staining. These findings concur with the view that bcl‐2 gene is frequently expressed in breast cancer, possibly through a hormonal‐dependent pathway.